Changfeng Pharmaceutical announced that the Group's clinical trial application for the fixed compound olotadine mometasone nasal spray developed independently by the company has been issued an acceptance notice by the China National Drug Administration.

Changfeng Pharmaceutical announced that the Group's clinical trial application for the fixed compound olotadine mometasone nasal spray developed independently by the company has been issued an acceptance notice by the China National Drug Administration.